10/11/2019 9:30:15 AM
Clovis Oncology: NICE Recommend That Women With Relapsed Ovarian Cancer In England Have Access To Rucaparib Through CDF
9/12/2019 4:05:18 AM
Clovis Oncology To Highlight Expanded Data From Rubraca TRITON And ARIEL Clinical Programs At ESMO Congress 2019
3/4/2019 3:12:24 AM
Clovis Oncology Announces Availability Of Rubraca Tablets For Women With Relapsed Ovarian Cancer In Germany
2/26/2019 8:29:18 AM
Clovis Q4 Net Loss $99.3 Mln Or $1.88/Shr Vs Loss $51.9 Mln Or $1.04/Shr Last Year
1/7/2019 8:20:09 AM
Clovis Oncology Expects $30.3 Mln -$30.8 Mln In Rubraca Product Revenues For Q4
12/4/2018 7:37:59 AM
Clovis Oncology : Patent Protection For Rubraca In Europe Confirmed Until At Least 2031
11/20/2018 8:08:07 AM
Clovis Announces Second US Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035
10/11/2018 4:10:29 PM
Clovis Oncology Appoints Robert Azelby And Richard Fair To Its Board Of Directors
10/2/2018 8:23:34 AM
Clovis Oncology Shares Up 8.72% In Premarket After Breakthrough Designation From FDA For Rubraca
10/2/2018 8:10:13 AM
Clovis Oncology Receives Breakthrough Therapy Designation For Rubraca For BRCA1/2-mCRPC